Attovia Therapeutics (ATTO) News
NASDAQ: ATTOHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
15.10-0.48 (-3.08%)
At close: Nov 20, 4:00 PM ET · Delayed 15 min
ATTO news summary
We found 4 recent headlines mentioning Attovia Therapeutics (ATTO): 0 in the past week and 4 in the past 30 days, most often from GlobeNewswire, Seeking Alpha, Nasdaq. For price context, ATTO is down 3.08% at $15.10. The most recent story, "Attovia Therapeutics, Inc. GAAP EPS of -$0.76", was published by Seeking Alpha on Nov 10, 2026.
Headlines link to the original publishers. MetaCap does not republish third-party articles.
Summary generated from market data by MetaCap's automated system. Methodology
Latest Attovia Therapeutics headlines
- Attovia Therapeutics, Inc. GAAP EPS of -$0.76Seeking Alpha
- Attovia Therapeutics Reports Third Quarter 2026 Financial Results and Provides a Corporate UpdateAnnounced positive topline 12-week Phase 1b results for ATTO-1310 in patients with chronic pruritus (CP) and high-itch atopic dermatitis (AD)GlobeNewswire
- Attovia Therapeutics Announces Positive Topline 12-Week Results from Phase 1b Study of ATTO-1310 in Patients with Chronic Pruritus and High-Itch Atopic DermatitisResults build on preliminary Week 4 findings, in which a single dose of ATTO-1310 demonstrated rapid, deep, and durable itch relief in patients with chronic pruritus (CP) and high-itch atopic…GlobeNewswire
- Attovia Therapeutics Becomes Oversold (ATTO)Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a…Nasdaq